#USA #San Diego #Class Action #Robbins LLP #Regencell

Class Action Lawsuit Against Regencell Bioscience Holdings Limited

Robbins LLP, a leader in shareholder rights, is bringing attention to a significant class action lawsuit aimed at Regencell Bioscience Holdings Limited (NASDAQ: RGC). This action affects all investors who acquired Regencell securities between October 28, 2024, and October 31, 2025. The case has unfolded against the backdrop of troubling allegations surrounding the company's vulnerability to market manipulation and the significant risks posed to its investors.

Allegations of Misleading Statements

According to the filed complaint, the defendants are accused of making false or misleading statements about Regencell's market condition. It is claimed that they failed to inform investors that Regencell was (1) subject to a stock manipulation scheme, (2) experiencing high market volatility which significantly endangered investors financially, and (3) at risk of increased scrutiny and regulation from government entities due to these vulnerabilities.

As highlighted in the lawsuit, the situation intensified on October 31, 2025, when Regencell disclosed an ongoing investigation by the U.S. Department of Justice (DOJ) related to its trading practices. This announcement resulted in Regencell's stock price plummeting by over 18% in a single day, highlighting the impact of the alleged mismanagement on shareholder investments.

What This Means for Investors

Investors who purchased shares during the specified period may find themselves at the center of this legal dispute. In the event that the case progresses, shareholders could be eligible to recover losses through participation in the class action. Those wishing to take a more active role in the litigation can also apply to serve as a lead plaintiff, which entails a more direct involvement in legal proceedings.

It's important to note that becoming a lead plaintiff does not obligate individuals to engage in the lawsuit process actively if they choose not to. Furthermore, all representation in this legal matter is structured on a contingency fee basis, meaning shareholders will not incur any fees unless they win a settlement or recovery.

Next Steps for Affected Shareholders

The timeline for potential involvement is critical. Shareholders interested in serving as lead plaintiff must submit their paperwork by June 23, 2026. Those who prefer not to take direct action will remain part of the class by default, eligible for any recovery that might follow the outcome of the case.

For further inquiries and information about participating in this class action, shareholders can contact Robbins LLP directly. The firm is reachable via phone at (800) 350-6003 or through a dedicated email to attorney Aaron Dumas, Jr. Additionally, parties interested in staying informed about developments in the case or similar legal actions against corporations can subscribe to Stock Watch by Robbins LLP.

Background on Robbins LLP

Established in 2002, Robbins LLP has cultivated a reputation for advocating shareholder rights effectively. The firm specializes in helping investors recover losses while pushing for enhanced corporate governance and accountability from business executives. Through their consistent legal efforts, they have assisted numerous shareholders in navigating similar situations and achieving favorable outcomes.

As the case against Regencell Bioscience Holdings Limited unfolds, affected investors should stay informed and consider their options concerning participation in the lawsuit. While significant uncertainty looms over the company and its stock, mobilizing in response to this situation with the help of experienced legal counsel can be a crucial step for safeguarding investments and pursuing justice.